SoftBank invests in a new USD 400m European tech fund of Mubadala
Category: #business  By Mateen Dalal  Date: 2019-02-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

SoftBank invests in a new USD 400m European tech fund of Mubadala

Mubadala would use the fund to invest between USD 5 million and USD 30 million in European technology startups

Japans conglomerate SoftBank Group has reportedly announced to have invested nearly half the amount for the recently launched USD 400 million technology fund by United Arab Emirates state-owned Mubadala Investment Company. As per trusted sources, the technology fund was unveiled last year by Mubadala Investment Company with an objective to back European startups.

Reportedly, the European venture fund would be operated from a new office in London. People with knowledge of the matter claim that the technology fund has already made a few undisclosed investments. A big investor in SoftBank’s Vision Fund, Mubadala Investment Company would utilize the fund to invest between USD 5 million and USD 30 million in European startups.

The launch of the European tech fund was made by Mubadala at London Tech Week last year. It was stated that Mubadala Ventures, the venture capital arm of Mubadala Investment Company, would manage the tech fund. Reportedly, Mubadala Ventures would also facilitate the process for European tech firms to build operations in Abu Dhabi to target the Middle East and Gulf markets.

Since its inception, SoftBank Group has participated as a strategic investor in the tech fund through its investment subsidiary, SIMI US Holdings I, Inc. The venture firm had released a statement during the launch which had noted that the fund would work closely with early-stage UK and other European funds. The firm would enlarge its fund of funds program as part of its European strategy and would invest in both emerging and established fund managers throughout the continent.

According to a report published by Channel NewsAsia, Mubadala was not immediately reachable for comment, while SoftBank did not respond to a request seeking comment.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
By Mateen Dalal

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristo...

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
By Mateen Dalal

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acqu...

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...